clinical utility
The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.
Illumina, Henry Ford Health Partner on Genomic Testing for Cardiovascular Patients
The partnership could yield data to support the use of whole-genome sequencing in treating and managing cardiovascular disease, the leading cause of death in the US.
Stakeholders are working to harmonize strategies for overcoming the challenges faced by new blood-based multi-cancer early detection assays.
The diagnostics subsidiary, created by Oxford Nanopore Technologies last year, plans to forge partnerships with clinical and industry partners.
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.